Robert Brass, MD
Ophthalmology · Latham, NYNPI 1326003682
Payments from drug & device makers
Across 367 payments — averaging $125.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$39K
- Alcon$2K
- Bausch & Lomb Americas Inc.$667
- AbbVie$554
- Sun Pharmaceutical Industries Inc.$553
- Ocular Therapeutix, Inc.$471
- plus $3K from 19 others
What the payments were for
- Consulting fees$6,58814%
- Speaking & faculty fees$26,89458%
- Travel & lodging$2,2465%
- Food & beverage$10,46723%
- Education$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 74 | $39,473 |
| Alcon | 56 | $1,663 |
| Bausch & Lomb Americas Inc. | 38 | $667 |
| AbbVie(2 entities) | 26 | $554 |
| Sun Pharmaceutical Industries Inc. | 25 | $553 |
| Ocular Therapeutix, Inc. | 26 | $471 |
| Tarsus Pharmaceuticals, Inc. | 21 | $430 |
| Oyster Point Pharma, Inc. | 18 | $349 |
| Harrow Eye, LLC | 2 | $304 |
| Mallinckrodt Hospital Products Inc. | 11 | $304 |
| Kala Pharmaceuticals, Inc. | 13 | $251 |
| Sight Sciences, Inc. | 6 | $244 |
| Novartis | 12 | $194 |
| Shire North American Group Inc | 8 | $152 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 8 | $141 |
| Dompe US, Inc. | 5 | $124 |
| Biotissue Holdings Inc. | 5 | $88 |
| Johnson & Johnson Surgical Vision, Inc. | 4 | $75 |
| Eyevance Pharmaceuticals LLC | 2 | $33 |
| Eyepoint US, Inc. | 2 | $30 |
| ANI Pharmaceuticals, Inc. | 1 | $29 |
| Thea Pharma Inc. | 1 | $25 |
| Ivantis, Inc | 1 | $24 |
| Omeros Corporation | 1 | $16 |
| Rayner Intraocular Lenses Limited | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$46,211 in reported general payments places this provider in the 90th percentile of 1,587 ophthalmology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 63 | $71,905 |
| XiidraLifitegrast | 41 | $56,615 |
| LumiganBimatoprost | 82 | $42,505 |
| Cyclosporine | 64 | $32,044 |
| CombiganBrimonidine Tartrate/Timolol | 38 | $19,717 |
| Travoprost | 86 | $16,049 |
| Bromfenac Sodium | 51 | $15,920 |
| Latanoprost | 647 | $11,762 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 57 | $10,855 |
| Alphagan PBrimonidine Tartrate | 17 | $10,390 |
| ZyletTobramycin/Lotepred Etab | 11 | $9,167 |
| Brinzolamide | 22 | $7,561 |
| Prednisolone Acetate | 182 | $6,316 |
| Brimonidine Tartrate | 70 | $6,144 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 18 | $6,118 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $554 | $144,517200 claims |
| Bausch & Lomb Americas Inc.Xiidra | $667 | $56,61541 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCZylet, Loteprednol Etabonate | $141 | $12,56028 claims |
| AlconSimbrinza | $1,663 | $6,11818 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,587 ophthalmology providers in New York.
Other ophthalmology in Latham
- Douglas JabsNew York$24.3M
- David RubaltelliBrooklyn$8.9M
- Philip FerroneGreat Neck$5.8M
- Eric DonnenfeldGarden City$2.6M
- Nathan RadcliffeNew York$2.4M
- Glenn StollerRockville Centre$2.1M
- Richard SpaideNew York$1.7M
- Paul HartmanRochester$1.6M
- Jason SlakterNew York$1.2M
- David ChuNew York$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.